Utilizing noncatalytic ACE2 protein mutant as a competitive inhibitor to treat SARS-CoV-2 infection

Utilizing noncatalytic ACE2 protein mutant as a competitive inhibitor to treat SARS-CoV-2 infection

IntroductionAngiotensin converting-enzyme 2 (ACE2) is an enzyme catalyzing the conversion of angiotensin 2 into angiotensin 1-7. ACE2 also serves as the receptor of several coronaviruses, including SARS-CoV-1 and SARS-CoV-2. Therefore, ACE2 could be utilized as a therapeutic target for treating thes...

Full description

Bibliographic Details
Main Authors:	Shengjiang Liu, Haifeng Chen, Xiangqun Chen, Ningguang Luo, Sameera Peraramelli, Xiaoming Gong, Mingwei John Zhang, Li Ou
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-04-01
Series:	Frontiers in Immunology
Subjects:	COVID-19 SARS-CoV-2 ACE2 neutralization protein engineering
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1365803/full

Similar Items

ACE2 Serum Levels as Predictor of Infectability and Outcome in COVID-19
by: María del Carmen Maza, et al.
Published: (2022-03-01)

SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses
by: Masaud Shah, et al.
Published: (2022-01-01)

ACE2 Receptor and Its Isoform Short-ACE2 Are Expressed on Human Spermatozoa
by: Marina Ramal-Sanchez, et al.
Published: (2022-03-01)

Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro
by: Latifa Zekri, et al.
Published: (2023-03-01)

An ACE2-Based Decoy Inhibitor Effectively Neutralizes SARS-CoV-2 Omicron BA.5 Variant
by: Haoran Zhang, et al.
Published: (2022-10-01)

Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals
by: Brian Grunau, et al.
Published: (2022-10-01)

The association of ACE1, ACE2, TMPRSS2, IFITM3 and VDR polymorphisms with COVID-19 severity
by: Zorana Dobrijević, et al.
Published: (2022-06-01)

Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
by: Bruce D. Wines, et al.
Published: (2022-07-01)

Calcium Signaling Pathway Is Involved in the Shedding of ACE2 Catalytic Ectodomain: New Insights for Clinical and Therapeutic Applications of ACE2 for COVID-19
by: Artemio García-Escobar, et al.
Published: (2022-01-01)

Killing Two Birds with One Stone by Administration of Soluble ACE2: A Promising Strategy to Treat Both Cardiovascular Diseases and SARS-CoV-2 Infection
by: Fengling Feng, et al.
Published: (2021-11-01)

Corrigendum: Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
by: Bruce D. Wines, et al.
Published: (2023-01-01)

An ACE2 decamer viral trap as a durable intervention solution for current and future SARS-CoV
by: Hailong Guo, et al.
Published: (2023-12-01)

Importance of ACE2 for SARS-CoV-2 Infection of Kidney Cells
by: Marie-Kristin Kroll, et al.
Published: (2023-03-01)

A Competitive Panning Method Reveals an Anti-SARS-CoV-2 Nanobody Specific for an RBD-ACE2 Binding Site
by: Siqi He, et al.
Published: (2023-02-01)

WERE SARS-COV-2 OR ACE-I RESPONSIBLE FOR ANGIOEDEMA OR WAS IT CAUSED BY A SECOND STRIKE? A CASE REPORT
by: Giorgio Monteleone
Published: (2023-10-01)

Genetically engineered Lactobacillus paracasei rescues colonic angiotensin converting enzyme 2 (ACE2) and attenuates hypertension in female Ace2 knock out rats
by: Xue Mei, et al.
Published: (2023-10-01)

SARS-CoV-2 Cellular Entry Is Independent of the ACE2 Cytoplasmic Domain Signaling
by: Thankamani Karthika, et al.
Published: (2021-07-01)

Vitamin D improves hepatic alterations in ACE1 and ACE2 expression in experimentally induced metabolic syndrome
by: Sara Mohater, et al.
Published: (2023-09-01)

Receptor-Binding Domain (RBD) Antibodies Contribute More to SARS-CoV-2 Neutralization When Target Cells Express High Levels of ACE2
by: Ariana Ghez Farrell, et al.
Published: (2022-09-01)

In Vitro Diagnostic Assay to Detect SARS-CoV-2-Neutralizing Antibody in Patient Sera Using Engineered ACE-2 Mini-Protein
by: Bruna Andersen Pereira de Jesus, et al.
Published: (2022-12-01)

Broadly Effective ACE2 Decoy Proteins Protect Mice from Lethal SARS-CoV-2 Infection
by: Mengjia Lu, et al.
Published: (2023-08-01)

Transcriptional regulation of SARS-CoV-2 receptor ACE2 by SP1
by: Hui Han, et al.
Published: (2024-02-01)

A tool for nuclear imaging of the SARS-CoV-2 entry receptor: molecular model and preclinical development of ACE2-selective radiopeptides
by: Darja Beyer, et al.
Published: (2023-04-01)

Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins
by: Sai Priya Anand, et al.
Published: (2020-09-01)

The ACE-2 in COVID-19 : foe or friend?
by: Dalan, Rinkoo, et al.
Published: (2021)

Association of ACE1 I/D rs1799752 and ACE2 rs2285666 polymorphisms with the infection and severity of COVID‐19: A meta‐analysis
by: Md. Abdul Aziz, et al.
Published: (2022-11-01)

“Molecular Masks” for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry
by: Satya Prakash Shukla, et al.
Published: (2021-08-01)

Variation in the ACE2 receptor has limited utility for SARS-CoV-2 host prediction
by: Nardus Mollentze, et al.
Published: (2022-11-01)

Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection
by: Natasja de Bruin, et al.
Published: (2022-01-01)

The impact of ACE2 polymorphisms (rs1978124, rs2285666, and rs2074192) and ACE1 rs1799752 in the mortality rate of COVID-19 in different SARS-CoV-2 variants
by: Farzaneh Sheikhian, et al.
Published: (2023-06-01)

Genotype variation of ACE and ACE2 genes affects the severity of COVID-19 patients
by: Ingrid Faustine, et al.
Published: (2023-09-01)

Pulmonary ACE2 expression in neonatal and adult rats
by: Depeng Zhao, et al.
Published: (2021-08-01)

Glycyrrhizin Inhibits SARS-CoV-2 Entry into Cells by Targeting ACE2
by: Ming-Feng He, et al.
Published: (2022-10-01)

Research Progress on the Cardiac Injury from ACE2 Targeting in SARS-CoV-2 Infection
by: Hao Sun, et al.
Published: (2021-01-01)

Molecular dynamic and bioinformatic studies of metformin-induced ACE2 phosphorylation in the presence of different SARS-CoV-2 S protein mutations
by: Amr Ahmed El-Arabey, et al.
Published: (2023-07-01)

ACE2 and TMPRSS2 expression in patients before, during, and after SARS-CoV-2 infection
by: Henrique Borges da Silva Grisard, et al.
Published: (2024-03-01)

Rapid screening of SARS-CoV-2 inhibitors via ratiometric fluorescence of RBD–ACE2 complexes in living cells by competitive binding
by: Lu Miao, et al.
Published: (2022-09-01)

Long Chain N3-PUFA Decreases ACE2 Protein Levels and Prevents SARS-CoV-2 Cell Entry
by: Shiqi Huang, et al.
Published: (2022-11-01)

Role of SARS-CoV-2 and ACE2 variations in COVID-19
by: Priya Antony, et al.
Published: (2021-06-01)

Analysis of the Role of N-Linked Glycosylation in Cell Surface Expression, Function, and Binding Properties of SARS-CoV-2 Receptor ACE2
by: Raymond Rowland, et al.
Published: (2021-10-01)